AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9443537
Drug: d-amphetamine (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine (5, 10 mg P.O.)
Trial: 9443537
Drug: Diazepam (2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (2.5, 5 mg P.O.)
Trial: 9443537
Drug: Tripelennamine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripelennamine (75 mg)
Trial: 7977316
Drug: nitrendipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nitrendipine (10 to 40 mg/d)
Trial: 7977316
Drug: enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril (5 to 20 mg/d)
Trial: 2686418
Drug: Ciprofloxacin 200
RxNorm normalized name: ciprofloxacin 200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 200 mg intravenously every 12 hours
Trial: 2686418
Drug: Ceftazidime 0.5
RxNorm normalized name: avibactam-ceftazidime 0.5 g-2 g intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 0.5 to 2 g intravenously every eight to 12 hours
Trial: 31705581
Drug: 10% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% lidocaine spray combined with 2% lidocaine gel
Trial: 31705581
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution spray combined with 2% lidocaine gel
Trial: 27957618
Drug: Corticosteroid local
RxNorm normalized name: Corticosteroids acting locally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid local injection
Trial: 23933953
Drug: Prednisolone 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 7.5 mg once daily (n = 12)
Trial: 23933953
Drug: Prednisolone 30
RxNorm normalized name: prednisolone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 30 mg once daily (n = 12)
Trial: 21799173
Drug: Cilostazol group
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol group (aspirin plus cilostazol)
Trial: 21799173
Drug: Clopidogrel group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel group (aspirin plus clopidogrel)
Trial: 15562366
Drug: Canarypox vector-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canarypox vector-based HIV vaccines (ALVAC-HIV)
Trial: 12815771
Drug: Inhalation anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation anaesthesia
Trial: 12815771
Drug: Mixed inhalation
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed inhalation and intravenous anaesthesia
Trial: 8315424
Drug: Doxorubicin 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 80 mg/m2
Trial: 8315424
Drug: Ifosfamide 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide 7.5 g/m2 plus Doxorubicin 60 mg/m2
Trial: 8315424
Drug: Mitomycin 8
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin 8 mg/m2 plus Doxorubicin 40 mg/m2 plus Cisplatin 60 mg/m2
Trial: 3554564
Drug: Thymopentin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopentin (50 mg daily for the first two weeks, then three times weekly)
Trial: 3554564
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline solution intravenously)
Trial: 22189383
Drug: Cisplatin-based neoadjuvant
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based neoadjuvant chemotherapy (NAC)
Trial: 22189383
Drug: Cisplatin-based neoadjuvant
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based neoadjuvant chemotherapy (NAC) with complete downstaging (CD)
Trial: 20163382
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) combined with nicotine patches plus cognitive behavioral group counseling for smoking cessation (n = 153)
Trial: 20163382
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) alone (n = 72)
Trial: 8704116
Drug: Intravenous calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous calcitriol (2 micrograms after each dialysis)
Trial: 8704116
Drug: Oral calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcitriol (2 micrograms after each dialysis)
Trial: 6414795
Drug: Oral long-term
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral long-term treatment with antiarrhythmic drugs (aprindine, mexiletine, disopyramide, amiodarone)
Trial: 31919123
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of activated and expanded haploidentical NK (NKAE) cells, two doses once a week, using a GMP K562‐mbIL15‐41BBL stimulus from a haploidentical donor and interleukin 2 subcutaneously.
Trial: 30575616
Drug: Office-based accommodative/vergence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Office-based accommodative/vergence therapy (OBAVT)
Trial: 29078971
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment without needle penetration
Trial: 25730341
Drug: Interoceptive exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interoceptive exposure (IE) through running, following a 3-day group cognitive behavioral therapy intervention.
Trial: 16518519
Drug: Oxerutins (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxerutins (2 g/day)
Trial: 16518519
Drug: Daflon (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daflon (3 tablets of 500 mg daily for 8 weeks)
Trial: 29786959
Drug: Ertugliflozin 15
RxNorm normalized name: ertugliflozin 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertugliflozin 15 mg with Sitagliptin 100 mg
Trial: 29786959
Drug: Ertugliflozin 15
RxNorm normalized name: ertugliflozin 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertugliflozin 15 mg with Metformin 1000 mg
Trial: 29786959
Drug: Ertugliflozin 15
RxNorm normalized name: ertugliflozin 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertugliflozin 15 mg with Glimepiride 1 mg
Trial: 29786959
Drug: Ertugliflozin 15
RxNorm normalized name: ertugliflozin 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertugliflozin 15 mg with Simvastatin 40 mg
Trial: 21703829
Drug: Cranberry juice,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice, twice a day for 6 weeks (including 2 weeks post-treatment)
Trial: 21703829
Drug: Placebo beverage,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo beverage, twice a day for 6 weeks (including 2 weeks post-treatment)
Trial: 18037444
Drug: Transition to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transition to Community program, involving interviews by an advanced practice psychiatric nurse, communication via prepaid cellular phones, and follow-up on medication compliance and outpatient appointments.
Trial: 12381235
Drug: Combined antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined antiretroviral therapy in elderly patients
Trial: 12381235
Drug: Antiretroviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral treatment and therapy guidelines
Trial: 12381235
Drug: Antiretroviral drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral drug dosage adjustment
Trial: 6449902
Drug: Intravenous mezlocillin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous mezlocillin, 260 mg/kg/day in six divided doses
Trial: 6449902
Drug: Intravenous mezlocillin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous mezlocillin, 450 mg/kg/day in six divided doses
Trial: 6449902
Drug: Combined results
RxNorm normalized name: omega-3 acid ethyl esters (USP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined results from both dosage regimens
Trial: 27693901
Drug: Stop-and-go methadone
RxNorm normalized name: Go-dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stop-and-go methadone titration method
Trial: 27693901
Drug: Progressive methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive methadone titration method
Trial: 24225312
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no thermal agent)
Trial: 19672115
Drug: Dead Sea
RxNorm normalized name: Cleanser Topical application Soap [MG217 DEAD SEA SOAP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dead Sea mineral-enriched body lotion (DS)
Trial: 19672115
Drug: Placebo lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lotion with no Dead Sea minerals (P1)
Trial: 19672115
Drug: Placebo lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lotion with no active ingredients (P2)
Trial: 7530168
Drug: m‐BACOD chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m‐BACOD chemotherapy
Trial: 2225700
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg mefloquine hydrochloride
Trial: 2225700
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg mefloquine hydrochloride
Trial: 2225700
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg and 1500 mg mefloquine hydrochloride
Trial: 31670238
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of all four image contrasts (FLAIR, T1, T2, proton density)
Trial: 21270194
Drug: Fasting Plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting Plasma Glucose (FPG) ≥ 126 mg/dL
Trial: 16197921
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium infusion (0.1 mmol/kg)
Trial: 14510997
Drug: TAC in
RxNorm normalized name: TAC Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC in Transfersome (2.5 micro g cm‐2)
Trial: 14510997
Drug: TAC cream
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAC cream (25 micro g cm‐2)
Trial: 14510997
Drug: TAC ointment
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAC ointment (25 micro g cm‐2)
Trial: 14510997
Drug: TAC cream
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAC cream
Trial: 1450797
Drug: Diclofenac 50
RxNorm normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 50 mg and Misoprostol 200 micrograms
Trial: 1450797
Drug: Diclofenac 50
RxNorm normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 50 mg and Placebo
Trial: 16230678
Drug: Weekly cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly cisplatin 40 mg/m2
Trial: 25691677
Drug: Androgen-Deprivation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen-Deprivation Therapy plus Radiotherapy (ADT+RT)
Trial: 25691677
Drug: Androgen-Deprivation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen-Deprivation Therapy alone (ADT)
Trial: 21199265
Drug: colesevelam 3.75
RxNorm normalized name: colesevelam 3.75 g oral powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: colesevelam 3.75 g/day
Trial: 9403260
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application of povidone-iodine
Trial: 9403260
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily application of povidone-iodine
Trial: 9403260
Drug: Once or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once or twice daily application of povidone-iodine
Trial: 7917797
Drug: Amoxycillin 250
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 250 mg three times daily
Trial: 25738794
Drug: Initial conservative
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial conservative treatment (subsequent evacuation allowed if deemed necessary)
Trial: 12271281
Drug: Cryotherapy followed
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryotherapy followed by topical imiquimod and salicylic acid
Trial: 9364674
Drug: S‐L* vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐L* vaccine (20 micrograms/dose)
Trial: 9364674
Drug: Engerix‐B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engerix‐B vaccine (20 micrograms/dose)
Trial: 3083705
Drug: Intravenous metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous metronidazole and ceftriaxone
Trial: 29912663
Drug: Stem cell
RxNorm normalized name: Stem cells, apheresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stem cell therapy (bone marrow-derived mononuclear cells)
Trial: 29912663
Drug: Compression therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression therapy alone (control group)
Trial: 27113487
Drug: Interim pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interim pressure garment (IPG) therapy (4-6 mmHg) applied post-operatively on day 5
Trial: 24831251
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) plus 10 mg zolpidem nightly
Trial: 21910714
Drug: 311-nm UVB
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 311-nm UVB therapy
Trial: 20216207
Drug: Metoclopramide (MTC)
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide (MTC) plus Dopamine (DA) infusion
Trial: 20216207
Drug: Metoclopramide (MTC)
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide (MTC) infusion
Trial: 8314480
Drug: Interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2b 3 MU three times weekly for three months
Trial: 8314480
Drug: Interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2b 3 MU three times weekly for six months
Trial: 8314480
Drug: Interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2b 6 MU two times weekly for six months
Trial: 8314480
Drug: Interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2b 6 MU three times weekly for six months
Trial: 27721533
Drug: Chloroquine 10
RxNorm normalized name: chloroquine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine 10 mg/kg on Day 1, 10 mg/kg on Day 2, and 5 mg/kg on Day 3
Trial: 24990776
Drug: Vipromak added
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vipromak added to treatment protocol
Trial: 24990776
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment scheme
Trial: 22677218
Drug: milnacipran 100
RxNorm normalized name: milnacipran 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: milnacipran 100 mg/d
Trial: 27945299
Drug: Neoadjuvant chemotherapy:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy: docetaxel 75 mg/m² and cisplatin 75 mg/m² D1 q 3 wks x 2, followed by cisplatin 40 mg/m² weekly x 6-8 concurrent with RT (66 Gy in 2-Gy fractions)
Trial: 27945299
Drug: Control arm:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control arm: concurrent cisplatin-RT as arm 1 without neoadjuvant chemotherapy
Trial: 11986439
Drug: Apple juice
RxNorm normalized name: apple juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apple juice (sorbitol 0.5 g/dL; 2.6:1 fructose-to-glucose ratio)
Trial: 7267475
Drug: prenylamine 180
RxNorm normalized name: prenylamine
DrugBank: Prenylamine (DB04825)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prenylamine 180 mg daily
Trial: 28129756
Drug: Motivational interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing and cognitive behavioural therapy based intervention for AUDs, administered over 16 sessions at 8 HIV clinics.
Trial: 23843062
Drug: Oxybutynin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin treatment (Group I)
Trial: 15555005
Drug: Fleet Prep
RxNorm normalized name: Fleet Prep Kit #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleet Prep Kit 3 (FPK #3) - single dose (45 ml) oral sodium phosphate (NaP), four bisacodyl tablets (5 mg), and one bisacodyl enema (10 mg)
Trial: 15555005
Drug: 4 L
RxNorm normalized name: PEG-4 laurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 L polyethylene glycol solution (PEG)
Trial: 11869753
Drug: Integrated, clinic-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated, clinic-based treatment delivery system emphasizing algorithm-driven somatotherapy, standardized patient education, and easy access to a primary mental health care provider.
Trial: 7946230
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (one-month course including passive listening and active singing)
Trial: 14671147
Drug: Cinacalcet (30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet (30, 40, or 50 mg)
Trial: 8788290
Drug: Pancreatic supplementation
RxNorm normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic supplementation therapy
Trial: 1289369
Drug: Selective decontamination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective decontamination of the digestive tract (SDD) with topical polymyxin, amphotericin B, and tobramycin throughout ITU stay, and intravenous ceftazidime for the first 3 days only.
Trial: 1289369
Drug: Contemporaneous control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contemporaneous control (CC)
Trial: 1289369
Drug: SDD and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDD and CC groups
Trial: 4081704
Drug: M‐M‐RR II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M‐M‐RR II vaccine
Trial: 30376687
Drug: Combined hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined hormone therapy with estrogen and progestin
Trial: 27220529
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) with infrared laser to two forehead sites while seated (total 8 min, 1064 nm continuous wave, 250 mW/cm(2), 60 J/cm(2) per site of 13.6 cm(2))
Trial: 27220529
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (LLLT + EX)
Trial: 8594267
Drug: Oral beta
RxNorm normalized name: Cloral betaine
DrugBank: Chloral betaine (DB01494)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral beta carotene, 50 mg per day for a median of 4.3 years
Trial: 8594267
Drug: Initial plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial plasma beta carotene concentrations in the highest quartile (>0.52 micromol/L)
Trial: 25045434
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus Megestrol Acetate (MA) - 160 mg of MA daily plus 0.5 g of metformin thrice daily
Trial: 25045434
Drug: Megestrol Acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol Acetate (MA) alone - 160 mg of MA daily
Trial: 19414708
Drug: Assessment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment of antidepressant response
Trial: 15451222
Drug: IVIG 1
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 1 g/kg per month
Trial: 9886730
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training group (daily exercise training for 3 months)
Trial: 2591384
Drug: iopentol 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iopentol 0.3 g I/kg
Trial: 2591384
Drug: iopentol 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iopentol 0.6 g I/kg
Trial: 2591384
Drug: iopentol 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iopentol 1.2 g I/kg
Trial: 778307
Drug: Ribavirin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin (200 mg, three times daily)
Trial: 778307
Drug: Amantadine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine (100 mg, twice daily)
Trial: 26566148
Drug: Atorvastatin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin + Amiodarone